Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities

被引:11
作者
Chataway, Jeremy [1 ,2 ]
Murphy, Niamh [3 ]
Khurana, Vivek [4 ]
Schofield, Helen [5 ]
Findlay, John [5 ]
Adlard, Nicholas [3 ]
机构
[1] UCL, UCL Queen Sq Inst Neurol, Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat,Fac Brain Sci, London, England
[2] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Corp Malaysia Sdn Bhd, Patient Access Solut, Petaling Jaya, Malaysia
[5] Oxford PharmaGenesis, Oxford, England
关键词
Secondary progressive multiple sclerosis; cost of illness; economic value of life; systematic review; UNMET NEEDS TRIBUNE; TREATMENT EXPERIENCE; BURDEN; MS;
D O I
10.1080/03007995.2021.1904860
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To identify evidence in the literature presenting the economic and humanistic (based on health state utility values [HSUVs]) burden of multiple sclerosis (MS) and report the incremental burden of secondary progressive MS (SPMS) compared with relapsing-remitting MS (RRMS). Methods: Electronic databases (Embase, MEDLINE, MEDLINE In-Process, Cochrane Library) and other relevant repositories were systematically searched from the date of inception until November 2019 for evidence on the economic burden of MS, or HSUVs in patients with MS. Data were extracted from studies investigating cost data or HSUVs for patients with SPMS compared with RRMS. Results: In total, 25 studies were identified that reported data on the economic and HSUV burden of SPMS versus RRMS: 18 studies reported cost data and nine presented HSUVs. Overall, costs associated with SPMS were consistently higher than those for RRMS. Major cost drivers appeared to shift following transition from RRMS to SPMS, with higher direct medical costs associated with RRMS than with SPMS, while the opposite was true for direct non-medical costs and indirect costs. In all studies presenting HSUVs specifically in patients with SPMS, the disease burden was greater (indicated by lower HSUV scores or a negative regression coefficient vs RRMS) for patients with SPMS than for those with RRMS. Fatigue and psychological stress (including depression) were identified as key drivers of this reduced health-related quality of life (HRQoL). Conclusions: Our findings indicate that SPMS is associated with higher costs and more substantial HRQoL decrements than RRMS. These results highlight the substantial unmet need for effective treatments that can slow disease progression in patients with SPMS, which, in turn, would reduce the rate of HRQoL deterioration and increasing healthcare costs.
引用
收藏
页码:995 / 1004
页数:10
相关论文
共 53 条
[1]   Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study [J].
Achiron, Anat ;
Chapman, Joab ;
Magalashvili, David ;
Dolev, Mark ;
Lavie, Mor ;
Bercovich, Eran ;
Polliack, Michael ;
Doniger, Glen M. ;
Stern, Yael ;
Khilkevich, Olga ;
Menascu, Shay ;
Hararai, Gil ;
Gurevich, Micharel ;
Barak, Yoram .
PLOS ONE, 2013, 8 (08)
[2]   The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy [J].
Amato, MP ;
Battaglia, MA ;
Caputo, D ;
Fattore, G ;
Gerzeli, S ;
Pitaro, M ;
Reggio, A ;
Trojano, M .
JOURNAL OF NEUROLOGY, 2002, 249 (02) :152-163
[3]   The Use of Health State Utility Values in Decision Models [J].
Ara, Roberta ;
Brazier, John ;
Zouraq, Ismail Azzabi .
PHARMACOECONOMICS, 2017, 35 :S77-S88
[4]  
Atlas of MS, 2013, MAPP MULT SCLER WORL
[5]   Beyond Depression: Predictors of Self-Reported Cognitive Function in Adults Living With MS [J].
Beier, Meghan ;
Amtmann, Dagmar ;
Ehde, Dawn M. .
REHABILITATION PSYCHOLOGY, 2015, 60 (03) :254-262
[6]   The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrad County, Hungary [J].
Bencsik, K ;
Rajda, C ;
Füvesi, J ;
Klivényi, P ;
Járdánházy, T ;
Török, M ;
Vécsei, L .
EUROPEAN NEUROLOGY, 2001, 46 (04) :206-209
[7]   Can We Treat Secondary Progressive Multiple Sclerosis Now? [J].
Bhatia, Rohit ;
Singh, Nishita .
ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2019, 22 (02) :131-136
[8]   The mediating role of processing speed in the relationship between depressive symptoms and cognitive function in multiple sclerosis [J].
Blair, Mervin ;
Gill, Sascha ;
Gutmanis, Iris ;
Smolewska, Kathy ;
Warriner, Erin ;
Morrow, Sarah A. .
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 2016, 38 (07) :782-794
[9]  
Blinkenberg M., 2019, 35 C EUR COMM TREATM
[10]   Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims [J].
Bruno, Detournay ;
Marc, Debouverie ;
Ouarda, Pereira ;
Dominique, Seyer ;
Marc, Soudant ;
Laurene, Courouve ;
Khalil, Jomaa ;
Jonathan, Epstein ;
Francis, Guillemin .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36